Navigation Links
Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Date:8/23/2007

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the Thomas Weisel Partners Healthcare Conference 2007 on Wednesday, September 5, 2007 at 3:15 p.m. (Eastern Time) at the Four Seasons Hotel in Boston, Massachusetts.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts: Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

amerriweather@monogrambio.com

Jeremiah Hall

Feinstein Kean Healthcare

Tel: 415 677-2700

jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... August 09, 2018 , ... MedEvolve, Inc. ... engagement and analytics software and services for physician practices, announced today the company’s ... history. After back-to-back record quarters in Q2 and Q3 last year, the company ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... announces research results on the significant impact of a proprietary biofield energy ... , The preclinical research assessed biomarkers for systemic and organ-specific inflammation, as ...
(Date:7/26/2018)... ... July 26, 2018 , ... Ariadne Afaganis, an evidence-based ... energy treated nutraceutical to improve anti-inflammatory and immune function responses. , Biomarkers for ... preclinical research, were significantly reduced. Results are as follows:, ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... for managing clinical trial patient and supplies data through its flagship IXRS® ... on IRT: Best Practices.” , This podcast features both Almac thought leaders and ...
Breaking Biology Technology:
(Date:7/26/2018)... ... July 25, 2018 , ... Boston ... executives on September 4, 2018 at The Hilton Boston Back Bay Hotel. This ... business development experiences and dissect the most relevant deals in biotech. , George ...
(Date:7/26/2018)... ... July 26, 2018 , ... The Conference Forum has confirmed the agenda for ... 24, 2018 at the Marriott Copley Place in Boston, MA. , Daniel Karlin, MD, ... as program chair to lead the discussion on how and when to implement mobile/digital ...
(Date:7/25/2018)... ... ... pioneering Duchenne muscular dystrophy clinical trial is now recruiting patients at two sites in ... the need to enroll patients. , “There is no cure for Duchenne, and ... a clinical trial,” said Catherine Jayasuriya, the founder and executive director of Coalition Duchenne, ...
Breaking Biology News(10 mins):